WHO. Coronavirus disease (COVID-2019) situation reports, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (2020).
Gupta, A. et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 26, 1017–1032 (2020).
Petersen, E. et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect. Dis. 20, e238–e244 (2020).
Richardson, S. et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 323, 2052–2059 (2020).
Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 369, eabc8511 (2020).
Kuri-Cervantes, L. et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci. Immunol. 5, eabd7114 (2020).
Song, J.-W. et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat. Commun. 11, 3410 (2020).
Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity 52, 910–941 (2020).
Horby, P. et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 384, 693–704 (2021).
Li, L. et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: a randomized clinical trial. JAMA 324, 460–470 (2020).
Salama, C. et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N. Engl. J. Med. 384, 20–30 (2021).
Zhou, T. et al. Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus. Stem Cells Int. 2020, 6518508 (2020).
Hashmi, S. et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 3, e45–e52 (2016).
Chan, M. C. W. et al. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc. Natl. Acad. Sci. USA 113, 3621–3626 (2016).
Chen, J. et al. Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: a Hint for COVID-19 Treatment. Eng. (Beijing, China) 6, 1153–1161 (2020).
Matthay, M. A. et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir. Med. 7, 154–162 (2019).
Simonson, O. E. et al. In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. Stem Cells Transl. Med. 4, 1199–1213 (2015).
Wilson, J. G. et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir. Med. 3, 24–32 (2015).
Zheng, G. et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir. Res. 15, 39 (2014).
Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8, 420–422 (2020).
BMJ (Clin. Res. Ed.). 371, m3862 (2020).
Pei, G. et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J. Am. Soc. Nephrol. 31, 1157–1165 (2020).
Puelles, V. G. et al. Multiorgan and Renal Tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590–592 (2020).
Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet (Lond. Engl.) 395, 1417–1418 (2020).
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
Tan, M. et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology 160, 261–268 (2020).
Zhang, J.-Y. et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat. Immunol. 21, 1107–1118 (2020).
Front. Immunol. 11, 1049 (2020).
Ogega, C. O. et al. Durable SARS-CoV-2 B cell immunity after mild or severe disease. J. Clin. Investig. 131, e145516 (2021).
Cell Stem Cell 22, 824–833 (2018).
Pittenger, M. F. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Med. 4, 22 (2019).
Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Sci. (N. Y., N. Y.) 284, 143–147 (1999).
J. Clin. Med. 8, 1025 (2019).
Zumla, A. et al. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancingongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy – achieving global consensus and visibility forcellular host-directed therapies. Int. J. Infect. Dis: Off. Publication Int. Soc. Infect. Dis. 96, 431–439 (2020).
Wu, J. et al. Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs. Cell Prolif. 53, e12944 (2020).
Leng, Z. et al. Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 11, 216–228 (2020).
Tang, L. et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front. Med. 14, 664–673 (2020).
Meng, F. et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct. Target. Ther. 5, 172 (2020).
Hashemian, S.-M. R. et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem cell Res. Ther. 12, 91 (2021).
Sengupta, V. et al. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 29, 747–754 (2020).
Chen, X. et al. Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects. J. Infect. 81, 647–679 (2020).
Peng, H. et al. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. Stem Cell Res. Ther. 11, 291 (2020).
Liang, B. et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine 99, e21429 (2020).
Sanchez-Guijo, F. et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine 25, 100454 (2020).
Häberle, H. et al. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. J. Inten. Care Med. 36, 681–688 (2021).
Shu, L. et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res. Ther. 11, 361 (2020).
Shi, L. et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target. Ther. 6, 58 (2021).
Lanzoni, G. et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem cells Transl. Med. 10, 660–673 (2021).
Nat. Med. 25, 1037–1044 (2019).